DXM (dextromethorphan)

Browse DXM (dextromethorphan) Content

“The results of this year’s Monitoring the Future survey demonstrate that prevention through education works,” Consumer Healthcare Products Association (CHPA) President and CEO Scott Melville said.

Dec 13, 2016

A recent study conducted by Charles River Associates, a leading global consulting firm, has quantified the savings consumers and the healthcare system receive from the over-the-counter (OTC) availability of the widely used cough suppressant dextromethorphan (DXM).

Nov 1, 2016

Government officials have tried to balance the positives of OTC access against the negatives of potential abuse. This paper aims to inform this discussion by quantifying various costs that would result if products with DXM were converted from OTC to Rx.

Oct 1, 2016

Substance Abuse Treatment, Prevention, and Policy recently published a case study authored by CHPA about the association’s efforts to curb teen abuse of OTC cough medicine containing dextromethorphan.

Jun 27, 2016

CHPA released the following statement today in support of a Delaware law prohibiting the sale of OTC medicines containing the cough suppressant dextromethorphan (DXM) to minors.

Jun 17, 2016

CHPA is pleased to lend its strong support for the DXM Abuse Prevention Act (S. 2994), introduced into the U.S. Senate by Senators Bob Casey Jr. (D-PA) and Lisa Murkowski (R-AK).

May 16, 2016

CHPA, which represents leading manufacturers of OTC cough medicines, strongly supports this legislation and is joined many by substance abuse prevention organizations such as the Community Anti-Drug Coalitions of America and the Partnership for Drug-Free Kids.

Apr 20, 2016

CHPA released the following statement today in support of a Florida law prohibiting the sale of OTC medicines containing the cough suppressant dextromethorphan (DXM) to minors.

Apr 1, 2016

Filter Results